Evidence map›Paper›PMID 40823439›Full record

ArticleJBMR plus2025

Combined antiresorptive and new anabolic drug approach in osteogenesis imperfecta zebrafish models.

Cecilia Masiero, Francesca Tonelli, Carla Aresi, Marta Filibian, Daria Larionova, Silvia Cotti, Filippo Doria, Camilla Torriani, Paola Bertuccio, Anna Odone and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in JBMR plus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Cecilia MasieroDepartment of Molecular Medicine, Biochemistry Unit, University of Pavia, 27100 Pavia, Italy.
Francesca TonelliDepartment of Molecular Medicine, Biochemistry Unit, University of Pavia, 27100 Pavia, Italy.
Carla AresiDepartment of Molecular Medicine, Biochemistry Unit, University of Pavia, 27100 Pavia, Italy.
Marta FilibianCentro Grandi Strumenti, University of Pavia, 27100 Pavia, Italy.
Daria LarionovaEvolutionary Developmental Biology Group, Department of Biology, Ghent University, 9000 Ghent, Belgium.
Silvia CottiDepartment of Molecular Medicine, Biochemistry Unit, University of Pavia, 27100 Pavia, Italy.ORCID https://orcid.org/0000-0001-5143-5563
Filippo DoriaDepartment of Chemistry, University of Pavia, 27100 Pavia, Italy.ORCID https://orcid.org/0000-0002-1308-1060
Camilla TorrianiDepartment of Public Health and Experimental and Forensic Medicine, Unit of Biostatistics and Clinical Epidemiology, University of Pavia, 27100 Pavia, Italy.
Paola BertuccioDepartment of Public Health and Experimental and Forensic Medicine, Unit of Hygiene, University of Pavia, 27100 Pavia, Italy.ORCID https://orcid.org/0000-0002-2002-0127
Anna OdoneDepartment of Public Health and Experimental and Forensic Medicine, Unit of Hygiene, University of Pavia, 27100 Pavia, Italy.
Simona VillaniDepartment of Public Health and Experimental and Forensic Medicine, Unit of Biostatistics and Clinical Epidemiology, University of Pavia, 27100 Pavia, Italy.
Antonio RossiDepartment of Molecular Medicine, Biochemistry Unit, University of Pavia, 27100 Pavia, Italy.
Paul Eckhard WittenEvolutionary Developmental Biology Group, Department of Biology, Ghent University, 9000 Ghent, Belgium.
Antonella ForlinoDepartment of Molecular Medicine, Biochemistry Unit, University of Pavia, 27100 Pavia, Italy.ORCID https://orcid.org/0000-0002-6385-1182

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Osteogenesis imperfecta (OI) is a family of heritable collagen I-related skeletal disorders for which, to date, no definitive cure is available. Individuals with OI are mainly treated with bisphosphonates that enhance bone mass by inhibiting bone resorption. However, new strategies combining antiresorptive molecules with bone anabolic drugs are likely to provide valid alternatives for skeletal health, protecting physiological bone turnover. Recently, cellular stress has been identified as a therapeutic target in both dominant and recessive forms of OI characterized by overmodified collagen I. The chemical chaperone 4-phenylbutyrate (4PBA) successfully ameliorated cell homeostasis in both in vitro and in vivo OI models. In this study, dominant

Indexed as

bisphosphonatechemical chaperoneendoplasmic reticulum stressosteoblastsosteoclastsosteocytesosteogenesis imperfectaskeletonzebrafish

Identifiers

PMID40823439
PMCPMC12356371

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.